All treatments
InjectionWeight LossIn stock

Mounjaro® injection

Branded once-weekly tirzepatide, the recognizable Lilly pen patients ask for by name in the weight-loss conversation. Run a Mounjaro®-aware weight-loss program with intake, billing, refill, and pharmacy workflows wired into one backend.

Launch this programSee the stack
Mounjaro tirzepatide pen
Dose
Once weekly
Typical loss · 72 wks
−15% to −20%
Format
Weekly subcutaneous pen injection
Dose range
2.5 mg to 15 mg once weekly
Rx required
Yes, licensed provider review
Use case
Weight management with dual-incretin therapy
About the medication

The Lilly tirzepatide pen patients ask for by name

Mounjaro® is Eli Lilly's branded once-weekly tirzepatide. While it is FDA-labeled for type 2 diabetes, it is one of the most-recognized GLP-1 pens in the weight-loss conversation. Tirzepatide activates both GIP and GLP-1 receptors, and real-world weight outcomes at the higher Mounjaro® doses typically range from 15% to 20% over 6 to 18 months.

  • Same molecule as Zepbound®, both produce strong weight loss with dual-incretin agonism
  • Useful for weight-loss patients who recognize Mounjaro® by name from earlier coverage
  • Tirzepatide's GIP + GLP-1 mechanism gives a higher weight-loss ceiling than semaglutide brands
  • Helps programs serve patients arriving with brand-specific requests
Mechanism
Dual GIP and GLP-1 receptor agonist
Delivery
Pre-filled single-dose pen, once weekly subcutaneous
Onset
Appetite changes during escalation, weight loss continues for 60+ weeks
Oversight
Provider review for indication, history, and dose escalation
Expected results

High-ceiling weight loss from a dual-incretin brand

Tirzepatide's dual GIP and GLP-1 mechanism gives Mounjaro® one of the highest weight-loss ceilings among approved GLP-1 brands. Outcomes reflect tirzepatide trials and real-world Mounjaro® use at the 10 mg to 15 mg maintenance levels.

~16%
Typical weight loss
at 15 mg over 72 weeks in tirzepatide trials
~91%
Patients losing ≥5%
at higher tirzepatide doses (SURMOUNT-1)
~57%
Patients losing ≥15%
at the 15 mg dose in SURMOUNT-1
Mean change in body weight
% change from baseline · weeks 0–68
Mounjaro® 15 mgPlacebo
At week 68
−16.0%
Mounjaro® 15 mg
At week 68
−2.5%
Placebo
Net difference
−13.5 pts
vs. placebo

Illustrative, based on tirzepatide trial outcomes (SURPASS and SURMOUNT) and real-world Mounjaro® use at the 10 mg and 15 mg doses. Mounjaro® is FDA-labeled for type 2 diabetes; use for chronic weight management is off-label and at provider discretion.

Dosing protocol

Standard titration schedule

Mounjaro® labeling starts at 2.5 mg weekly for 4 weeks, then increases in 2.5 mg increments every 4 weeks based on tolerability and response. Weight-management programs commonly target the 10 mg or 15 mg maintenance dose.

  1. 1
    Weeks 1–4
    2.5 mg
    Initiation only, GI tolerance
  2. 2
    Weeks 5–8
    5 mg
    First up-titration
  3. 3
    Weeks 9–12
    7.5 mg
    Optional step-up
  4. 4
    Weeks 13–16
    10 mg
    Common mid-program weight-loss dose
  5. 5
    Weeks 17–20
    12.5 mg
    Higher-dose escalation
  6. 6
    Week 21+
    15 mg
    Maximum labeled maintenance dose
The Turbopills stack for this program

Everything you need to run a Mounjaro®-aware weight-loss program

Pick the pieces you want. Use your own brand, your own providers, your own price, powered by a single, compliant backend.

Product website & ad landing pages
Turbopills AI Studio — ad images & videos
Beta
Dynamic intake forms
Billing & subscriptions
Provider review & e-Rx
Pharmacy order routing
Refills & auto-ship
Patient communications
Experiments & A/B tests
Beta
Ready to launch

Launch a Mounjaro®-aware weight-loss program in weeks, not quarters.

The platform ships the intake flow, billing, subscriptions, refill workflows, and the operator console your team works in. Bring your licensed providers and pharmacy partners; we wire everything into one backend so you launch in weeks, not quarters.

Talk to our teamBrowse treatments

Marketing and educational content only. Clinical details on this page are summarized from publicly available sources to help operators scope a program — they are not medical advice, dosing instructions, or a recommendation for any individual patient. Real patient care requires a licensed provider and a compliant pharmacy partner; Turbopills provides the software that helps brands run the program around them.

Trademark notice. Mounjaro® is a registered trademark of Eli Lilly and Company. Turbopills is not affiliated with, endorsed by, or sponsored by Eli Lilly. References to the brand are for educational and operator-scoping purposes only.

Related

Other weight-loss treatments